Cargando…

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer

SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) represents a heterogeneous group of breast cancers that lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal factor 2 (HER2) amplifications. This triple negativity represents a challenge in choosing the right treatment, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brumec, Maša, Sobočan, Monika, Takač, Iztok, Arko, Darja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037213/ https://www.ncbi.nlm.nih.gov/pubmed/33915941 http://dx.doi.org/10.3390/cancers13071642

Ejemplares similares

Clinical features and their effect on outcomes of patients with triple negative breast cancer with or without lymph node involvement
por: Sobočan, Monika, et al.
Publicado: (2019)

Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management
por: Gorenšek, Rok, et al.
Publicado: (2023)

Inquiry and Computer Program Onko-Online: 25 Years of Clinical Registry for Breast Cancer at the University Medical Centre Maribor
por: Arko, Darja, et al.
Publicado: (2019)

Gynaecological cancers and their cell lines
por: Skok, Kristijan, et al.
Publicado: (2021)

Survival of Node-negative Breast Cancer Patients Treated at the University Medical Centre Maribor in the Period 2000–2009
por: Fokter Dovnik, Nina, et al.
Publicado: (2017)

Cervix-Online Computer Program: 27 Years of Hospital-based Clinical Registry for Cervical Cancer at The University Medical Centre Maribor
por: Lovrec, Vida Gavric, et al.
Publicado: (2021)

The Perspectives of Fertility Preservation in Women with Endometrial Cancer
por: Knez, Jure, et al.
Publicado: (2021)

Changes in the Extracellular Matrix in Endometrial and Cervical Cancer: A Systematic Review
por: Padežnik, Tjaša, et al.
Publicado: (2023)

Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer
por: Ovcaricek, Tanja, et al.
Publicado: (2019)

MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
por: Skok, Kristijan, et al.
Publicado: (2021)

The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer
por: Sobočan, Monika, et al.
Publicado: (2020)

Low Selenium Levels in Amniotic Fluid Correlate with Small-For-Gestational Age Newborns
por: Ogrizek-Pelkič, Ksenija, et al.
Publicado: (2020)

Long Term Results of Follow-up After HPV Self-sampling with Devices Qvintip and HerSwab in Women Non-attending Cervical Screening Programme
por: Bokan, Teodora, et al.
Publicado: (2021)

Advances in Diagnostics and Management of Gestational Trophoblastic Disease
por: Lukinovic, Nusa, et al.
Publicado: (2022)

Retained surgical needle and gauze after cesarean section and adnexectomy: a case report and literature review
por: Gavrić Lovrec, Vida, et al.
Publicado: (2018)

Data on metabolomic profiling of ovarian cancer patients' serum for potential diagnostic biomarkers
por: Kozar, Nejc, et al.
Publicado: (2018)

Pre-treatment Risk Assessment of Women with Endometrial Cancer: Differences in Outcomes of Molecular and Clinical Classifications in The Slovenian Patient Cohort
por: Knez, Jure, et al.
Publicado: (2021)

Targeting the androgen receptor in triple-negative breast cancer: current perspectives
por: Mina, Alain, et al.
Publicado: (2017)

What Role do Androgens Play in Endometrial Cancer?
por: Maček, Petra, et al.
Publicado: (2023)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
por: Khadela, Avinash, et al.
Publicado: (2022)

Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
por: Asano, Yuka, et al.
Publicado: (2017)

Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features
por: Astvatsaturyan, Kristine, et al.
Publicado: (2018)

Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer
por: Sobočan, Monika, et al.
Publicado: (2022)

Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients
por: Dovnik, Nina Fokter, et al.
Publicado: (2016)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer
por: Jinna, Nikita, et al.
Publicado: (2022)

Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations
por: Pistelli, Mirco, et al.
Publicado: (2014)

BCL11A confers cell invasion and migration in androgen receptor-positive triple-negative breast cancer
por: Wang, Xin, et al.
Publicado: (2020)

Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy
por: Peddi, Parvin F., et al.
Publicado: (2012)

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
por: Cuenca-López, María D, et al.
Publicado: (2014)

Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
por: Thakkar, A., et al.
Publicado: (2016)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
por: Speers, Corey, et al.
Publicado: (2017)

Association and implications in triple negative and triple positive breast cancer: Relationship with sociodemographic and reproductive factors in Pakistan
por: Fatima, Faria, et al.
Publicado: (2018)

Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis
por: Zhang, Li, et al.
Publicado: (2015)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1
por: Song, Wei, et al.
Publicado: (2017)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
por: Wang, Changjun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_abr7kso3rheej15guljsc3tmuh